Projects overview

Sort by

Toggle all information

MORPHEUS | PROGNOSIS IMPROVEMENT OF UNPROVOKED VENOUS THROMBOEMBOLISM USING PERSONALIZED ANTICOAGULANT THERAPY

01-12-2023

-

30-11-2028

Show more information
EU-Programme-Call
Horizon Europe
HORIZON.2 Global Challenges and European Industrial Competitiveness
HORIZON.2.1 Health
HORIZON.2.1.0 Cross-cutting call topics
HORIZON-HLTH-2022-TOOL-11
HORIZON-HLTH-2022-TOOL-11-01 Optimising effectiveness in patients of existing prescription drugs for major diseases (except cancer) with the use of biomarkers

BIOTOOL-CHF | BIOmarker based diagnostic TOOLkit to personalize pharmacological approaches in congestive heart failure

01-10-2023

-

30-09-2028

Show more information
EU-Programme-Call
Horizon Europe
HORIZON.2 Global Challenges and European Industrial Competitiveness
HORIZON.2.1 Health
HORIZON.2.1.0 Cross-cutting call topics
HORIZON-HLTH-2022-TOOL-11
HORIZON-HLTH-2022-TOOL-11-01 Optimising effectiveness in patients of existing prescription drugs for major diseases (except cancer) with the use of biomarkers

PoCCardio | Personalised Medicine by using an Advanced Point-of-Care Tool for Stratified Treatment in High Risk Cardiovascular Patients (PoCCardio)

01-12-2023

-

30-11-2028

Show more information
EU-Programme-Call
Horizon Europe
HORIZON.2 Global Challenges and European Industrial Competitiveness
HORIZON.2.1 Health
HORIZON.2.1.0 Cross-cutting call topics
HORIZON-HLTH-2022-TOOL-11
HORIZON-HLTH-2022-TOOL-11-01 Optimising effectiveness in patients of existing prescription drugs for major diseases (except cancer) with the use of biomarkers

OPADE | Optimise and predict antidepressant efficacy for patient with major depressive disorders using multi-omics analysis and AI-predictive tool

01-12-2022

-

31-05-2027

Show more information
EU-Programme-Call
Horizon Europe
HORIZON.2 Global Challenges and European Industrial Competitiveness
HORIZON.2.1 Health
HORIZON.2.1.0 Cross-cutting call topics
HORIZON-HLTH-2022-TOOL-11
HORIZON-HLTH-2022-TOOL-11-01 Optimising effectiveness in patients of existing prescription drugs for major diseases (except cancer) with the use of biomarkers
Powered by Chris Decubber BV